No Data
Frontage (01521) granted 33.15 million share options.
Frontage (01521) announced in a statement that on October 30, 2024 (after the trading session), according to the public...
Frontage Records Lower Net Profit for Nine Months to September
frontage Holdings (01521.HK) net profit for the first three quarters fell sharply by 98% year-on-year.
Frontage Holdings (01521.HK) announced that the profit for the nine months ended September 30, 2024 was approximately 0.191 billion US dollars, a 3.6% year-on-year decrease. Net profit was around 0.2 million US dollars, a significant 98% year-on-year drop. Adjusted net profit was about 9.5 million US dollars, a decrease of 47.9% year-on-year.
Frontage Holdings (01521.HK) reported a profit of approximately 0.191 billion US dollars in the first three quarters, a 3.6% decrease year-on-year.
On October 29, Glonhui announced that Frontage Holdings (01521.HK) disclosed the unaudited third-quarter performance for the nine months ending on September 30, 2024, on the main board of the Hong Kong Stock Exchange (Stock Code: 3347) and the GEM of the Shenzhen Stock Exchange (Stock Code: 300347). In order to ensure that all shareholders can fairly and promptly obtain the company overview, the company hereby publishes the unaudited consolidated financial information of the group as follows:
The first batch of pharmaceutical fund's third quarter report is released! Shareholding in US stocks reduced, while increasing holdings in Hong Kong stocks and A-shares.
The first batch of fund managers exposed in the third quarter medical investment strategy, significantly increased the proportion of innovative drugs, especially the position of Hong Kong-listed innovative drugs with greater flexibility.
Abnormal movement hits the CRO concept in the morning, driven by innovative drug policies and expectations of Fed rate cuts, Pharmaron and Tigermed both rose more than 7%.
CRO concept rose in the morning, as of the time of publication, Frontage Holdings increased by 8.45%, Pharmaron increased by 7.64%, Tigermed increased by 7.99%, and Joinn Laboratories increased by 5.59%.
No Data
No Data